DiaMedica Therapeutics(NASDAQ) DMAC

DiaMedica Therapeutics Inc. makes medicines for brain and kidney disorders. Its lead drug helps patients with strokes and dangerous pregnancy complications. These treatments improve blood flow and protect the body's vital organs.

Treating Strokes and High-Risk Pregnancies

• Acute Ischemic Stroke Treatment: Synthetic protein DM199 aims to improve blood flow after a stroke caused by a blood clot.
• High-Risk Pregnancy Therapies: Treatments for preeclampsia, a condition involving high blood pressure, and fetal growth restriction.
• Inflammatory Condition Research: Early-stage program called DM300 intended for patients with severe inflammation of the pancreas.

Recent Milestones and Global Reach

• Commenced site initiations and enrollments for the ReMEDy2 stroke trial in six European countries as of August 1, 2026.
• Raised $30.0 million in net proceeds through a private placement of common shares in July 2025.
• Received approval from Health Canada in March 2026 to start a Phase 2 trial for early-onset preeclampsia.
• Earned Fast Track designation from the FDA for treating acute ischemic stroke with its lead candidate DM199.

What Makes the Science Unique?

The company creates man-made proteins using DNA technology to avoid the infection risks of using animal or human tissue. Its lead drug candidate mimics a natural enzyme to improve blood circulation without entering the blood system of a developing fetus.

Checking the Financial Pulse

• Net loss was $20.2 million for the six months ended June 30, 2026, compared to $15.4 million for the same period in 2025.
• Research and development expenses reached $16.1 million for the six-month period ended June 30, 2026, up from $11.5 million in 2025.
• Cash, cash equivalents, and marketable securities totaled $43.5 million as of June 30, 2026.
• Market capitalization was $379.4 million in Q2 2026, up 126.5% year over year.

The Big Picture

DiaMedica has evolved from early research to advanced clinical testing for its primary drug candidate. Its focus remains on high-risk medical conditions where few safe treatment options exist.